Novo Nordisk A/S





Real-time Estimate Cboe Europe 07:57:08 2024-02-23 am EST 5-day change 1st Jan Change
852.4 DKK -0.10% Intraday chart for Novo Nordisk A/S +0.29% +22.25%
This article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Novo Nordisk: EU could authorize Wegovy by April CF
Novo Nordisk: EU authorization for Wegovy by April? CF
European Medicines Agency Set to Decide on Expanded Use of Novo Nordisk's Obesity Drug by April MT
Weight-loss drugs could boost US GDP by 1% in coming years, Goldman says RE
Drugs, fashion and chips - the STOXX 600's 'Magnificent 4' RE
Europe's megacap appeal stokes stocks to record highs RE
Gerresheimer expects less growth in 2024 - dividend stable DP
European shares hit all-time highs, global momentum builds RE
India pharma companies develop versions of Wegovy to get in on weight-loss windfall RE
Health Care Down After Medtronic Earnings -- Health Care Roundup DJ
FMC shares slide as analysts focus on weaker patient volumes outlook RE
NOVO NORDISK : Barclays remains its Buy rating ZD
Almirall: share price surges after agreement with Novo Nordisk CF
Almirall Secures Global Rights for Blocking Monoclonal Antibody Under Deal with Novo Nordisk MT
Almirall S.A. Enters into an Exclusive License Agreement with Novo Nordisk CI
Eli Lilly, Novo Nordisk get growth stock status on weight-loss drug boost RE
Forget about rate cuts... Our Logo
The latest transactions by star fund managers Our Logo
Wegovy fuels sharp rise in use of weight-loss drugs for US youth RE
US families begin to embrace weight-loss drugs for their children RE
Health Care Climbs Amid Drug Shortages -- Health Care Roundup DJ
Wegovy packing supplier Catalent lays off 300 workers RE
Britain sees launch of Lilly's weight-loss drug Mounjaro RE
NOVO NORDISK : Jefferies reaffirms its Sell rating ZD
FDA warns online vendors selling misbranded weight-loss, diabetes drugs RE
Chart Novo Nordisk A/S
More charts
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes treatment products (78.9%); - rare disease treatment products (11.6%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.; - obesity treatment products (9.5%). Net sales are distributed geographically as follows: Europe/Middle East/Africa (25%), the United States (47.8%), North America (3.6%), China (9.2%) and other (14.4%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
853.2 DKK
Average target price
771.3 DKK
Spread / Average Target
1st Jan change Capi.
+22.25% 552 B $
+32.03% 693 B $
+2.37% 386 B $
+18.57% 328 B $
+14.05% 312 B $
+7.26% 210 B $
-5.87% 209 B $
-4.89% 197 B $
-4.31% 156 B $
-0.99% 153 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock Novo Nordisk A/S - Nasdaq Copenhagen
  4. News Novo Nordisk A/S
  5. European Equities Close Higher in Thursday Trading; Euro Area Inflation Falls More Than Expected
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance